Impact of Hyperuricemia on Psoriatic Arthritis

Sponsor

University Hospital, Strasbourg, France (Other)

Overall Status

Recruiting

CT.gov ID

NCT06125444

Collaborator

(none)

242

Enrollment

Location

40.2

Anticipated Duration (Months)

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Psoriatic arthritis and gout (linked to hyperuricemia) are two rheumatisms well known to rheumatologists. There are epidemiological and physiopathological arguments in favor of a non-fortuitous link between these two rheumatisms, which to date has not been established. There is currently no recommendation to treat hyperuricaemia without an episode of gout attack. We hypothesize that there is a link between hyperuricemia and severity of rheumatism. This would ultimately modify the therapeutic management of hyperuricemic patients followed for psoriatic arthritis.

Condition or Disease	Intervention/Treatment	Phase
Psoriatic Arthritis

Study Design

Study Type:

Observational

Anticipated Enrollment :

242 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

IImpact of Hyperuricemia on Psoriatic Arthritis

Actual Study Start Date :

Aug 24, 2020

Anticipated Primary Completion Date :

Dec 1, 2023

Anticipated Study Completion Date :

Dec 31, 2023

Outcome Measures

Primary Outcome Measures

Retrospectively determine the impact of hyperuricemia on the response to psoriatic arthritis treatments: inventory of the latest treatments in progress and the response to treatment according to the treating rheumatologist [Files analysed retrospectively from January 01, 2009 to December 31, 2019 will be examined]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Inclusion criteria:

Major subject (≥18 years old)
Subject with a history of psoriatic arthritis objectified according to the CIM 10-1 coding for patients followed in hospitalization at the HUS and HCC
Subject presenting psoriatic arthritis objectified during a consultation by an HCC rheumatologist
Among these two populations, all subjects for whom at least one serum uric acid assay was available in the medical file
Subject having not expressed, after being informed, opposition to the reuse of their data for research purposes

Exclusion criteria:

Subject who expressed their opposition to participating in the study
Subject who met the inclusion criteria but whose analysis of the medical file (anamnestic, clinical, biological and radiological data) led to a diagnostic reversal and therefore did not present with psoriatic arthritis
Subject under guardianship or curatorship
Subject under safeguard of justice